TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30646835

Group type: EXPERIMENTAL
Intervention: 30% 1RM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 80% 1RM
Number of subjects: 13
Study: 29258591

Group type: EXPERIMENTAL
Intervention: Economic support with community dialogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic support without community dialogue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25996534

Group type: EXPERIMENTAL
Intervention: Epidural steroid application after PELD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline treatment after PELD
Number of subjects: 100
Study: 23566344

Group type: EXPERIMENTAL
Intervention: Midlife COPD
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both pulmonary diseases combined (COPD and asthma) diagnosed in midlife
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Both pulmonary diseases combined diagnosed later in life
Number of subjects: 2000
Study: 21746979

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 241

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 241
Study: 19241215

Group type: EXPERIMENTAL
Intervention: Multimedia presentation (Group I, n=34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Case based discussion (Group II, n=34)
Number of subjects: 68
Study: 16426098

Group type: EXPERIMENTAL
Intervention: Childhood-onset bipolar illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to first treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for treatment outcome data acquisition
Number of subjects: 0
Study: 15232328

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/d)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Testosterone (up to 400 mg IM testosterone cypionate biweekly)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 11703431

Group type: EXPERIMENTAL
Intervention: Exercise consultation and standard exercise information
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard exercise information alone
Number of subjects: 26
Study: 9205633

Group type: EXPERIMENTAL
Intervention: etidronate 400 mg/day
Number of subjects: 109

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 109
Study: 8094485

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of 0.3‐0.5 ml sterile water
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sterile water group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up after 8 months
Number of subjects: 40
Study: 2959717

Group type: COMPARATOR
Intervention: rt-PA (0.75 mg/kg)
Number of subjects: 258

Group type: COMPARATOR
Intervention: rt-PA (40 or 80 mg)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: single chain rt-PA (100 mg total)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 258
Study: 29792839

Group type: EXPERIMENTAL
Intervention: Standard care plus a choice of nonpharmacologic pain management options (ambient music, etc.)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (ibuprofen 800 mg orally, lidocaine paracervical block, anticipatory guidance)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Standard care plus a choice of nonpharmacologic pain management options
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 74
Study: 26731446

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25894960

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate treatment (group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 72
Study: 25191599

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 193

Group type: COMPARATOR
Intervention: Water
Number of subjects: 193
Study: 20363690

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study: 18427045

Group type: EXPERIMENTAL
Intervention: CSE with dermoscopy
Number of subjects: 1328

Group type: COMPARATOR
Intervention: CSE without dermoscopy
Number of subjects: 1328
Study: 17081269

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study: 16083195

Group type: EXPERIMENTAL
Intervention: Thai-made levonorgestrel pill (0.75 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hungarian levonorgestrel pill (0.75 mg)
Number of subjects: 18
Study: 11283441

Group type: EXPERIMENTAL
Intervention: Low-volume single-set circuit (SSC; N = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Periodized high-volume multiple-set (MS; N = 12)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonexercising control (CON; N = 10)
Number of subjects: 34
Study: 9401829

Group type: EXPERIMENTAL
Intervention: Lubeluzole 2.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lubeluzole 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lubeluzole 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lubeluzole 15 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lubeluzole 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lubeluzole 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8099593

Group type: EXPERIMENTAL
Intervention: Cetirizine, 15 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3543236

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (high-dose methotrexate, Adriamycin, BCD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group)
Number of subjects: 59
Study: 31626314

Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DFT)
Number of subjects: 499211
Study: 28714771

Group type: EXPERIMENTAL
Intervention: Acute Static Stretching (ASS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warming-up exercise alone (Control)
Number of subjects: 60
Study: 27283187

Group type: EXPERIMENTAL
Intervention: Unique absorbable intradermic stitch (Group A)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Traditional closure technique (non-absorbable separated stitches) (Group B)
Number of subjects: 208
Study: 24699554

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Subcutaneous (SC) injection
Number of subjects: 19
Study: 22883272

Group type: EXPERIMENTAL
Intervention: Puerarin Injection
Number of subjects: 388

Group type: COMPARATOR
Intervention: Danshen Injection
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 388
Study: 20692030

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (2 mL, three oral doses at 6, 10, and 14 weeks of age)
Number of subjects: 5468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5468

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 5468
Study: 18657196

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Human insulin mix 50
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 16326239

Group type: EXPERIMENTAL
Intervention: Effleurage massage for 5 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest for 5 minutes
Number of subjects: 12
Study: 11985407

Group type: EXPERIMENTAL
Intervention: Increased total fat intake
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Increased total protein intake
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Increased saturated fat intake
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Increased unsaturated fat intake
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: Increased myristic fatty acid intake
Number of subjects: 1182
Study: 9862296

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy at 1.5W/cm2 (group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy at 0.8W/cm2 (group B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo ultrasound therapy at 0.0W/cm2 (group C)
Number of subjects: 18
Study: 8595799

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2146853

Group type: EXPERIMENTAL
Intervention: danazol
Number of subjects: 12

Group type: COMPARATOR
Intervention: goserelin
Number of subjects: 12
Study: 1070948

Group type: EXPERIMENTAL
Intervention: delta9-THC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31021404

Group type: EXPERIMENTAL
Intervention: Phosistos protocol (P-PDT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional protocol (C-PDT)
Number of subjects: 46
Study: 31006996

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CCT) group
Number of subjects: 959

Group type: COMPARATOR
Intervention: Non-CCT group
Number of subjects: 959
Study: 29113968

Group type: EXPERIMENTAL
Intervention: diclofenac (NSAID)
Number of subjects: 253

Group type: COMPARATOR
Intervention: norfloxacin (antibiotic)
Number of subjects: 253
Study: 26116627

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg titrated to 25 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23963306

Group type: EXPERIMENTAL
Intervention: mARble (mobile Augmented Reality learning)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Textbook learning (control group)
Number of subjects: 10
Study: 21457929

Group type: COMPARATOR
Intervention: Standard-fluence photodynamic therapy (PDT) at 50 J/cm²
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-fluence photodynamic therapy (PDT) at 25 J/cm²
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (Standard-fluence and Low-fluence PDT)
Number of subjects: 42
Study: 19344725

Group type: EXPERIMENTAL
Intervention: Single intranasal dose of oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 17893153

Group type: EXPERIMENTAL
Intervention: Altastaph (200 mg/kg in two infusions 24 hours apart)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Altastaph
Number of subjects: 40
Study: 15761542

Group type: EXPERIMENTAL
Intervention: Prednisolone (PD) 2.4-3.5 mg/m2 BSA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 10-15 mg/m2 BSA
Number of subjects: 44
Study: 11479392

Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 118
Study: 9755269

Group type: EXPERIMENTAL
Intervention: Nonspeculum collection method
Number of subjects: 686

Group type: COMPARATOR
Intervention: Speculum collection method
Number of subjects: 686
Study: 7923254

Group type: EXPERIMENTAL
Intervention: ESRD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ESRD + LVD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LVD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Handgrip response
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 2457422

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate + irradiation at 40 Gy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate
Number of subjects: 133
Study: 4808813

Group type: EXPERIMENTAL
Intervention: Erect position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 20
Study: 31841830

Group type: EXPERIMENTAL
Intervention: Web-based concept mapping education
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (not receiving web-based concept mapping education)
Number of subjects: 201
Study: 30406858

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 0
Study: 28407727

Group type: EXPERIMENTAL
Intervention: rtfMRI‐nf from the amygdala (N=19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (rtfMRI‐nf from a parietal region, N=17)
Number of subjects: 36
Study: 25854013

Group type: COMPARATOR
Intervention: Clomiphene (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture-moxibustion + Chinese medicine (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clomiphene + acupuncture-moxibustion + Chinese medicine (group C)
Number of subjects: 120
Study: 24058684

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg(‐1) of body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cellulose (PLA)
Number of subjects: 8
Study: 21043788

Group type: EXPERIMENTAL
Intervention: SmartRx Web program (intervention)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 346
Study: 19268900

Group type: EXPERIMENTAL
Intervention: MammoSite brachytherapy (34 Gy in 3.4-Gy fractions)
Number of subjects: 1440
Study: 16776407

Group type: EXPERIMENTAL
Intervention: Prilocaine plain
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Mepivacaine plain
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Articaine with epinephrine
Number of subjects: 1391
Study: 15307698

Group type: EXPERIMENTAL
Intervention: Xiaoyan Zhixue Capsule (XYZXC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenosoem (AC‐17)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 11267952

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1430

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 1430
Study: 9259359

Group type: EXPERIMENTAL
Intervention: Sodium chloride pills (60 mEq of sodium per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8481365

Group type: EXPERIMENTAL
Intervention: Doxorubicin (70 mg/m2)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Epirubicin (70 mg/m2)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mitozantrone (14 mg/m2)
Number of subjects: 87

Group type: COMPARATOR
Intervention: All agents
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Doxorubicin or Epirubicin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mitozantrone
Number of subjects: 87
Study: 3102153

Group type: EXPERIMENTAL
Intervention: Oral fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral protein
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin‐induced hypoglycaemia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous arginine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral carbohydrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control days
Number of subjects: 12
Study: 28888220

Group type: EXPERIMENTAL
Intervention: 200 mg immediate-release co-crystal of tramadol-celecoxib (CTC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg immediate-release tramadol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg celecoxib
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg immediate-release tramadol and 100 mg celecoxib
Number of subjects: 30
Study: 27159349

Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Number of subjects: 25
Study: 25183978

Group type: EXPERIMENTAL
Intervention: Intermittent subglottic secretion drainage (SSD)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no SSD)
Number of subjects: 76
Study: 22542983

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 70
Study: 20868506

Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fat diet
Number of subjects: 108

Group type: COMPARATOR
Intervention: Moderate carbohydrate, increased protein diet
Number of subjects: 108
Study: 19031222

Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (rhCG)
Number of subjects: 125

Group type: COMPARATOR
Intervention: urinary human chorionic gonadotropin (uhCG)
Number of subjects: 125
Study: 16308443

Group type: EXPERIMENTAL
Intervention: Plaferon LB (5 mg/ml - 3 ml daily inhalations)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (inert solution)
Number of subjects: 43
Study: 12531809

Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m(2)/d for 28 days in induction, plus taper)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Prednisone (40 mg/m(2)/d)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: IV 6-mercaptopurine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Oral 6-mercaptopurine
Number of subjects: 1000
Study: 14610016

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1703

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1703

Group type: COMPARATOR
Intervention: Standard therapy (no abciximab)
Number of subjects: 1703
Study: 9440388

Group type: EXPERIMENTAL
Intervention: High-RS diet (amylomaize starch, 55.2 +/- 3.5 g RS/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-RS diet (available cornstarch, 7.7 +/- 0.3 g RS/d)
Number of subjects: 12
Study: 8591965

Group type: EXPERIMENTAL
Intervention: Prenephrectomy therapy
Number of subjects: 0
Study: 2693404

Group type: EXPERIMENTAL
Intervention: Epidural blood patch
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 18
Study: 892242

Group type: EXPERIMENTAL
Intervention: Early contact group (45 minutes of private skin to skin contact immediately after birth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed contact group (45 minutes of private skin to skin contact 12 hours after birth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no period of skin to skin contact)
Number of subjects: 60
Study: 30790528

Group type: EXPERIMENTAL
Intervention: Hypothetical intervention to increase a woman's sense of control of her life before behavioral weight loss efforts
Number of subjects: 0
Study: 28216412

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT; 40min; 4×4 intervals 90% peak heart rate)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT; 47min 70% HRpeak)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-Intensity Continuous Training (LICT; 47min 50% HRpeak)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study: 24619945

Group type: EXPERIMENTAL
Intervention: Heated, humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 76
Study: 23455033

Group type: EXPERIMENTAL
Intervention: Abciximab and heparin
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 1721
Study: 21796128

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 58

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 58
Study: 19587440

Group type: EXPERIMENTAL
Intervention: Tongxinluo (4 capsules once, 3 times per day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 39
Study: 16709464

Group type: EXPERIMENTAL
Intervention: Ramelteon 4mg
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study: 15290731

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 671
Study: 11778566

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 25.2‐30.6 Gy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no PCI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study: 9298332

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ethanol (0.25 g/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 25
Study: 8333931

Group type: EXPERIMENTAL
Intervention: New non-preserved artificial tear (sodium chloride 0.34% W/W, hydroxyethylcellulose 0.44% W/W)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other tear substitutes
Number of subjects: 30
Study: 28528536

Group type: EXPERIMENTAL
Intervention: R+D (10 mL of 0.25% ropivacaine + 0.5μg/kg dexmedetomidine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: R (10 mL of 0.25% ropivacaine)
Number of subjects: 60
Study: 27224446

Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (ASA) 100mg per day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral aspirin (ASA) 100mg per day via gastric tube
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall response to aspirin (both IV and oral)
Number of subjects: 22
Study: 25222173

Group type: EXPERIMENTAL
Intervention: Higher baseline Perceived Vulnerability (PV)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Increase in Perceived Vulnerability (PV) from baseline to end of treatment
Number of subjects: 267
Study: 22492823

Group type: EXPERIMENTAL
Intervention: Post-dilution HDF
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mid-dilution HDF
Number of subjects: 14